GlassScriptPhysician profile
David Farnsworth
NPI 1750434577
$5,774.70
in general payments reported to CMS, 2019-2025
51 companies · $812 in 2025
The $812 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $340 · 2021: $908 · 2022: $825 · 2023: $1,198 · 2024: $1,110 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,119.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $959.70 | 2021-2025 | |
| Amgen INC. | $650.61 | 2019-2025 | Evenity, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $578.74 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $492.24 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $395.30 | 2019-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $328.43 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $317.84 | 2019-2025 | |
| Kyowa Kirin, INC. | $192.92 | 2023 | Crysvita |
| Sanofi-Aventis U.S. LLC | $183.76 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $156.14 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $121.96 | 2019-2022 | |
| Shield Therapeutics INC | $106.94 | 2023-2025 | Accrufer |
| Antares Pharma, INC. | $101.00 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $96.86 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $84.82 | 2019-2024 | Spravato |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Farnsworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.